Anti-IgE monoclonal antibodies as potential treatment in COVID-19

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Coronavirus disease 2019 (COVID-19) can cause irreversible organ damage due to a hyperinflammatory immune response, termed cytokine storm.
• Immunoglobulin E (IgE) is implicated in hypersensitivity, respiratory infections, and mast cell activation, potentially worsening COVID-19 outcomes.
• IgE negatively correlates with Interferon-alpha (IFN-α) production, impairing the immune response against viral infections.

Purpose of the Study:

• To explore the role of Immunoglobulin E (IgE) in the pathogenesis of COVID-19.
• To investigate the potential of anti-IgE therapy, specifically omalizumab, as an immunotherapy for COVID-19.

Main Methods:

• Review of existing literature on COVID-19, immune responses, IgE, and anti-IgE therapies.
• Analysis of the mechanisms by which IgE influences viral infections and inflammation.
• Evaluation of omalizumab's effects on IgE, inflammatory cells, and COVID-19 severity.

Main Results:

• COVID-19 is characterized by a cytokine storm, a severe immune overreaction damaging multiple organs.
• IgE plays a significant role in hypersensitivity and respiratory infections, potentially exacerbating COVID-19.
• Omalizumab, an anti-IgE drug, has shown potential in reducing COVID-19 severity and duration by inhibiting IgE and inflammatory cells like neutrophils.

Conclusions:

• Blockade of IgE represents a promising therapeutic strategy for managing COVID-19.
• Anti-IgE agents like omalizumab may serve as effective immunotherapies for COVID-19 patients.
• Targeting IgE could mitigate the hyperinflammatory response and organ damage associated with severe COVID-19.